Abstract

The links between inflammatory disease and cancer are well-defined: some chronic inflammatory diseases increase the risk of cancer; production of inflammatory mediators is downstream of many oncogenic mutations; cells and mediators of inflammation are present in the tumour microenvironment and inhibition of inflammatory pathways has potential in cancer treatment and prevention.

This session will highlight some recent research on the importance of inflammatory pathways during cancer treatment and relapse.